Literature DB >> 10391696

Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma.

A K Stewart, S Trudel, B M Al-Berouti, D M Sutton, J Meharchand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10391696

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Phase II trial of clarithromycin and pamidronate therapy in myeloma.

Authors:  T C Morris; L Ranaghan; J Morrison
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

2.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

Review 3.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

4.  Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.

Authors:  Salvador Alonso; Meng Su; Jace W Jones; Sudipto Ganguly; Maureen A Kane; Richard J Jones; Gabriel Ghiaur
Journal:  Oncotarget       Date:  2015-06-20

5.  Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report.

Authors:  Kern Y Chai; Anna L Byrne; Ian M Morison
Journal:  J Med Case Rep       Date:  2018-05-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.